ArticlePloS one2026
Protective effect of cannabinoid type II receptor ligand on bleomycin-induced pulmonary fibrosis in mice.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the protective effects of the CB2R ligand compound COCA (N-(3-chloro-2-methylphenyl)-5-(4-hydroxyphenyl)-1,2-oxazole-3-carboxamide) against bleomycin (BLM)-induced pulmonary fibrosis in mice. Compound COCA was identified via AI-driven virtual screening from the ChEMBL database. Forty male C57BL/6J mice were randomly divided into five groups: control, model (BLM), low-dose COCA, high-dose COCA, and pirfenidone. Pulmonary fibrosis was induced by intratracheal BLM administration in the model and treatment groups. Pathological evaluation, ELISA, immunofluorescence, and Western blot were conducted.The results showed that COCA significantly alleviated BLM-induced inflammation and fibrosis. ELISA demonstrated decreased serum levels of TNF-α and IL-6 in the treated groups compared to the BLM group (P < 0.01). Immunofluorescence indicated reduced expression of Col-I and Col-III in the treated groups (P < 0.01). Western blot analysis revealed an upregulation of CB2R in the BLM group, and enhanced expressions of Nrf2 and Smad7 in the treated groups (P < 0.01).In conclusion, AI-driven virtual screening enabled the identification of the CB2R ligand COCA, which binds to CB2R, activates the Nrf2/Smad7 pathway, downregulates related cytokines, and plays a therapeutic and protective role in pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.